PMID- 33021006
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20230919
IS  - 1549-490X (Electronic)
IS  - 1083-7159 (Print)
IS  - 1083-7159 (Linking)
VI  - 26
IP  - 2
DP  - 2021 Feb
TI  - Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor 
      Receptor Inhibitors: Overview, Prevention, and Management Guidelines.
PG  - e316-e326
LID - 10.1002/onco.13552 [doi]
AB  - Fibroblast growth factor receptor (FGFR) tyrosine kinases, which are expressed on 
      the cell membrane, are involved in a wide range of biological functions such as 
      cell proliferation, survival, migration, and differentiation. The identification 
      of FGFR fusions and other alterations in a wide range of solid tumors, including 
      cholangiocarcinoma and bladder cancer, has resulted in the development of several 
      selective FGFR inhibitors for use in these indications, for example, 
      infigratinib, erdafitinib, derazantinib, pemigatinib, and futibatinib. In 
      addition to the typical adverse events associated with tyrosine kinases, the FGFR 
      inhibitors appear to give rise to a number of adverse events affecting the skin. 
      Here we describe these skin events, which include the more common nail adverse 
      events (e.g., onycholysis), palmar-plantar erythrodysesthesia syndrome, and 
      stomatitis, as well as less common reactions such as calciphylaxis. This review 
      aims to provide oncologists with an understanding of these dermatologic events 
      and proposes guidelines for the management of treatment-emergent dermatologic 
      adverse events. Awareness of possible adverse events associated with specific 
      drugs should allow physicians to educate patients as to what to expect and 
      implement effective management plans at the earliest possible opportunity, 
      thereby preventing premature discontinuation while maintaining patient quality of 
      life. IMPLICATIONS FOR PRACTICE: Identification of fibroblast growth factor 
      receptor (FGFR) aberrations in cholangiocarcinoma and bladder cancer led to 
      development of selective FGFR inhibitors for these indications, based on clinical 
      benefit and safety profiles. The most frequent adverse events (AEs) include those 
      affecting skin, hair, and nails, a unique class effect of these agents. These are 
      usually mild to moderate in severity. This work reviewed skin AEs reported with 
      FGFR inhibitors and provides management guidelines for physicians, aiming to 
      increase awareness of skin events and provide effective treatment strategies. 
      Early intervention and effective management may improve treatment adherence, 
      optimize outcomes, and improve quality of life.
CI  - (c) 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf 
      of AlphaMed Press.
FAU - Lacouture, Mario E
AU  - Lacouture ME
AUID- ORCID: 0000-0002-4818-3710
AD  - Memorial Sloan Kettering Cancer Center, New York, New York, USA.
FAU - Sibaud, Vincent
AU  - Sibaud V
AD  - Department of Oncodermatology, Institut Universitaire du Cancer Toulouse 
      Oncopole, Toulouse, France.
FAU - Anadkat, Milan J
AU  - Anadkat MJ
AD  - Division of Dermatology, Department of Medicine, Washington University School of 
      Medicine, Saint Louis, Missouri, USA.
FAU - Kaffenberger, Benjamin
AU  - Kaffenberger B
AD  - Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
FAU - Leventhal, Jonathan
AU  - Leventhal J
AD  - Yale University, New Haven, Connecticut, USA.
FAU - Guindon, Kathleen
AU  - Guindon K
AD  - QED Therapeutics, San Francisco, California, USA.
FAU - Abou-Alfa, Ghassan
AU  - Abou-Alfa G
AD  - Memorial Sloan Kettering Cancer Center, New York, New York, USA.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201028
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Morpholines)
RN  - 0 (Pyrimidines)
RN  - 0 (Pyrroles)
RN  - 0 (Receptors, Fibroblast Growth Factor)
RN  - Y6BX7BL23K (pemigatinib)
SB  - IM
MH  - *Antineoplastic Agents/adverse effects
MH  - *Bile Duct Neoplasms/drug therapy
MH  - Bile Ducts, Intrahepatic
MH  - Humans
MH  - Morpholines
MH  - Pyrimidines
MH  - Pyrroles
MH  - Quality of Life
MH  - Receptors, Fibroblast Growth Factor/therapeutic use
PMC - PMC7873330
OTO - NOTNLM
OT  - Dermatologic
OT  - Drug-related side effects and adverse events
OT  - Fibroblast growth factor receptor
OT  - Guidelines
COIS- Disclosures of potential conflicts of interest may be found at the end of this 
      article.
EDAT- 2020/10/07 06:00
MHDA- 2021/06/22 06:00
PMCR- 2021/02/01
CRDT- 2020/10/06 05:35
PHST- 2020/04/06 00:00 [received]
PHST- 2020/09/25 00:00 [accepted]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/10/06 05:35 [entrez]
PHST- 2021/02/01 00:00 [pmc-release]
AID - ONCO13552 [pii]
AID - 10.1002/onco.13552 [doi]
PST - ppublish
SO  - Oncologist. 2021 Feb;26(2):e316-e326. doi: 10.1002/onco.13552. Epub 2020 Oct 28.